Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of BRY812 in LIV-1-positive advanced gynecologic malignancies
CTR20254219Phase 2Active
- Sponsor
- Zhejiang Boye Biotech
- Start
- Oct 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BRY812 in gynecological cancer, ovarian cancer, endometrial cancer (EC), clear cell ovarian cancer, sponsored by Zhejiang Boye Biotech. Started Oct 2025; status: active.
02
Drugs
BRY812
03
Conditions
gynecological cancerovarian cancerendometrial cancer (EC)clear cell ovarian cancer
Beyond the preview
Go deeper on CTR20254219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254219.